Phase 3 N=103 Home-based Exercise Via a Telecommunications System
Functional Limitation
Primary: Knee Extension Strength — 20.4; 19.5 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=222 Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
Breast Cancer
Primary: Number of Patients With Progression-free Survival (PFS) at 24 Weeks — 67; 68 Participants
Phase 3 N=731 Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Prostate Cancer
Primary: All Cause Mortality — 171; 183 Participants
Phase 3 N=109 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Sarcoma
Primary: Number of Patients With Complete or Partial Response Assessed by RECIST Criteria — 63 percentage of participants
Phase 3 N=117 Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
Schizophrenia
Primary: Mean Clinical Global Impression Severity Score (CGI-S) From Baseline Through End of Study- - Safety Population. — 2.6; 1.0; 2.3; 1.1 units on a scale
Phase 3 N=2,203 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass
Ischemic Heart Disease
Primary: Short-term End Point — 61; 77 participants
Phase 3 N=7,808 A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
Osteoporosis
Primary: Number of Participants With New Vertebral Fractures — 264; 86 Participants — p=<0.0001
Phase 3 N=676 A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18 — -0.47; -0.97; -1.06 Percent — p=<0.001
Phase 3 N=624 Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Influenza
Primary: Time to Resolution of All Clinical Symptoms of Influenza as Reported by the Subjects — 109.1; 116.7; 95.5 Hours
Phase 3 N=157 Zinc for the Treatment of Herpes Simplex Labialis (HSL)
Herpes Simplex Labialis
Primary: Zicam Was Compared to Placebo as a Treatment of Recurrent HSL From the Date and Time of the Initiation of Therapy Until the Date and Time of Resolution of the Lesion or…
Phase 3 N=171 Blue Light Device for Pain Therapy
Low Back Pain · Low Back Pain, Recurrent · Musculoskeletal Pain
Primary: Change From Baseline (Mean of Three Measurements at Screening, Prior to Treatment Visit 1 and Treatment Visit 1 Pretreatment) in the Average Visual Analog Scale (VAS)…
Phase 3 N=449 Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Rosacea
Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale
Phase 3 N=16 Insulin Delivery Using Microneedles in Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Onset Time (Tmax) — 30; 52 Minutes
Phase 3 N=250 Denosumab Adherence Preference Satisfaction Study
Osteoporosis
Primary: Adherence With Treatment in the First Treatment Period — 95; 111; 29; 15 Participants — p=0.0259
Phase 3 N=847 PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Cancer · Colon Cancer · Colorectal Cancer
Primary: Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy — 5.7; 2.4 percentage of participants — p=0.014